TGFB1 and triple-negative breast carcinoma: TGF-β levels increase following chemotherapy, which promotes epithelial–mesenchymal transition (EMT), the development of cancer stem-like cells (CSCs), and drug resistance, particularly in triple-negative breast cancer (TNBC).